ScholarLens Back to search
2002•Chinese Journal of New Drugs and Clinical RemediesRequires access

Topiramate in add-on therapy of refractory epilepsy: a clinical multicenter study

Zhou Sheng

Open publisher page 0 citations

Abstract

AIM: To investigate the efficacy of topiramate (TPM) in the add on treatment of various types of refractory epilepsy seizures. METHODS: Two hundred and eighteen patients with refractory epilepsy were all treated with antiepileptic drugs (AEDs). The method of desage adding was used. The dosage adding period was 8 wk, 25 mg·d -1 of TPM at the begining and the target dosage was 200 mg·d -1 , After 12 wk of observation, TPM treatment was prolonged. RESULTS: After TPM treatment 26 patients (12.3 %) became seizure free, 59 patients (28.0 %) were ≥75 % seizure reduction, 107 patients (50.7 %) were ≥50 % seizure reduction, 19 patients (9.0 %) remained unacceptable seizure control. Five patients (2.3 %) were discontinue treatment with adverse reactrons, two patients were lost contact with reason not clear. CONCLUSION: TPM is a very effective new AED and worthy of clnical application and dissemination.

About this research paper

What this paper is about

AIM: To investigate the efficacy of topiramate (TPM) in the add on treatment of various types of refractory epilepsy seizures. METHODS: Two hundred and eighteen patients with refractory epilepsy were all treated with antiepileptic drugs (AEDs). The method of desage adding was used. The dosage adding period was 8 wk, 25 mg·d -1 of TPM at the begining and the target dosage was 200 mg·d -1 , After 12 wk of observation, TPM treatment was prolonged. RESULTS: After TPM treatment 26 patients (12.3 %) became seizure free, 59 patients (28.0 %) were ≥75 % seizure reduction, 107 patients (50.7 %) were ≥50 % seizure reduction, 19 patients (9.0 %) remained unacceptable seizure control. Five patients (2.3 %) were discontinue treatment with adverse reactrons, two patients were lost contact with reason not clear. CONCLUSION: TPM is a very effective new AED and worthy of clnical application and dissemination.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM: To investigate the efficacy of topiramate (TPM) in the add on treatment of various types of refractory epilepsy seizures. METHODS: Two hundred and eighteen patients with refractory epilepsy were all treated with antiepileptic drugs (AEDs). The method of desage adding was used. The dosage adding period was 8 wk, 25 mg·d -1 of TPM at the begining and the target dosage was 200 mg·d -1 , After 12 wk of observation, TPM treatment was prolonged. RESULTS: After TPM treatment 26 patients (12.3 %) became seizure free, 59 patients (28.0 %) were ≥75 % seizure reduction, 107 patients (50.7 %) were ≥50 % seizure reduction, 19 patients (9.0 %) remained unacceptable seizure control. Five patients (2.3 %) were discontinue treatment with adverse reactrons, two patients were lost contact with reason not clear. CONCLUSION: TPM is a very effective new AED and worthy of clnical application and dissemination.

Key concepts: Topiramate, Refractory (planetary science), Medicine, Epilepsy, Adverse effect, Anesthesia, Clinical efficacy, Surgery

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Topiramate in add-on therapy of refractory epilepsy: a clinical multicenter study — Research Paper | ScholarLens